Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vericel CorpVCEL · Entity 4481 | Director | April 29, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vericel Corp
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,995 |
Reported balance
After 2026-04-29 transaction · row 1
1 source rowRow 1 · 2026-04-29 · Exercise / conversion · Acquired 3,200 · Balance 32,995 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-29 · Exercise / conversion · Acquired 3,200 · Balance 0 F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 3,200 |
Reported balance
After 2026-04-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-29 · Grant · Acquired 3,200 · Balance 3,200 F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026. F4: No expiration date for this type of award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.43 · Expires 2036-04-29 | Direct | 8,000 |
Reported balance
After 2026-04-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-29 · Grant · Acquired 8,000 · Balance 8,000 F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.
F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
F4: No expiration date for this type of award.
F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 28, 2021, the Reporting Person deferred the receipt of 2,600 shares of Common Stock and instead received 2,600 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. F4 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Company's Non-Employee Directors' Deferred Compensation Program. The units will be payable only in shares of Common Stock after the end of the Reporting Person's service on the Company's Board of Directors. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 28, 2021, the Reporting Person deferred the receipt of 2,600 shares of Common Stock and instead received 2,600 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. Vested shares will be delivered to the Reporting Person following termination of service on the Company's Board of Directors. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-04-28 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 29, 2020, the Reporting Person deferred the receipt of 1,750 shares of Common Stock and instead received 1,750 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. F4 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Company's Non-Employee Directors' Deferred Compensation Program. The units will be payable only in shares of Common Stock after the end of the Reporting Person's service on the Company's Board of Directors. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 29, 2020, the Reporting Person deferred the receipt of 1,750 shares of Common Stock and instead received 1,750 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · derivative · entry 5 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 17,500 | $23.55 | $412,125.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · nonDerivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,795 Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 15,000 | $2.76 | $41,400.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 15,000 | $3.74 | $56,100.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:17 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001593968-20-001090 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2030-04-29 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:17 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-001090 · primary_01.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-001090 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2020 or the date of the first Annual Meeting of Stockholders following May 1, 2019. The first Annual Meeting of Stockholders occurred on April 29, 2020. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-001090 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on May 1, 2019. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:03 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-19-001033 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2020 or the date of the first Annual Meeting of Stockholders following May 1, 2019. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:03 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $16.62 | $0.00 |
DisclosureSEC source: 0001593968-19-001033 · primary_01.xml · derivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2029-05-01 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001593968-19-000213 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, became exercisable in equal monthly installments, contingent upon continued service to the Company, with the first vesting date on June 3, 2017, which was one month after the date on which the option was granted. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 17,500 | $2.63 | $46,025.00 |
DisclosureSEC source: 0001593968-19-000213 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 3, 2018 19:23 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001593968-18-000730 · primary_01.xml · derivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company Read SEC document |
| May 03, 2017 Filed May 5, 2017 20:10 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001593968-17-000665 · primary_01.xml · derivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-05-03 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.